Original Publication Date: 1 September, 2014
Publication / Source: International Journal of Endocrine Oncology
Authors: Libero Santarpia, Camilo Jimenez
Despite a better knowledge in the molecular signaling pathways involved in the pathogenesis of medullary thyroid carcinoma (MTC), this disease, when metastatic at diagnosis, shows an unfavorable prognostic outcome [1,2]. Recent clinical trials using specific targeted therapies have shown promising results, but the low rates of partial or complete responses and the short duration of responses in these types of patients, has prompted researchers to investigate for novel biological mechanisms of the disease and to take into account to develop alternative targeted therapies [2,3].